"TBSF" (20%) Human Albumin Solution

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

Albumin, Quantity: 200 g/L

Disponible depuis:

CSL Behring Australia Pty Ltd

DCI (Dénomination commune internationale):

Albumin

forme pharmaceutique:

Injection, solution

Composition:

Excipient Ingredients: octanoate; sodium

Mode d'administration:

Intravenous

Unités en paquet:

50mL, 100mL

classe:

Medicine Listed (Export Only)

Type d'ordonnance:

(S1) This Schedule is intentionally blank

indications thérapeutiques:

Hypoproteinaemia in the acutely ill patient TBSF (20%) Human Albumin Solution is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. Shock. TBSF (20%) Human Albumin Solution may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4 - 5% human albumin is preferred when available. Burns. Extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins resulting in hypovolaemic shock and circulatory failure.

Descriptif du produit:

Visual Identification: Clear, slightly viscous almost colourless, yellow or green; Container Type: Vial; Container Life Time: 4 Years; Container Temperature: Store below 30 degrees Celsius

Statut de autorisation:

Listed (Export Only)

Date de l'autorisation:

2006-03-01